CuriRx has a 13,000 square foot, well equipped facility. CuriRx's employees have a combined experience of over 150 years. CuriRx offers high quality product development services. Our staff has subject matter expertise and can execute complex projects in a variety of areas including:

Drug Product Development/injectables-All Modalities
o Pre-Formulation and Formulation Development, Lyophilization Cycle Development
o Parenteral (IM, IV, SC, IT), Ocular, Topicals, Orals
o Nanotechnology

We have successfully developed over 100 clinical formulations, both liquid and lyophilized dosage forms.

The scientists at CuriRx have proven track records with successes in developing the commercial products like Humira and Synagis (high con mAbs), Blincyto (Bispecific) and Gattex (Peptide), etc.

CuriAnalyticsTM/Analytical testing and development-All modalities
o Utilizes state-of-art, high resolution mass spectrometry.
o Characterization/CMC support
o Analytical Development
o Development, Qualification, and Validation
o GMP Stability studies and Product characterization
o GMP Quality Testing Services

Bulk Drug Substance Development for biologics
o Cell line development, Upstream and Downstream Development, capacity up to 50 Liters single use bioreactors

🔗 http://curirx.com

CONNECT:

Indu Javeri, President and CEO
📧 ijaveri@curirx.com
📞 978.290.9162
205 Lowell Street, 1C
Wilmington, MA 01876